Literature DB >> 2758235

Platelet-activating factor (Paf) antagonist, WEB 2086, protects against Paf-induced hypotension in Macaca fascicularis.

A W Stanton1, T Izumi, J W Antoniw, P J Piper.   

Abstract

1. The actions of intravenously administered platelet-activating factor (Paf) (0.1-3.33 nmol kg-1) and the effect of a recently described Paf antagonist, WEB 2086, were investigated in the anaesthetized open-chest monkey, Macaca fascicularis. 2. Paf dose-dependently reduced blood pressure, left ventricular pressure (LVP) and its first differential LV dP/dt. 3. Mean pulmonary artery pressure, recorded in three animals, was essentially unchanged by any dose of Paf. 4. WEB 2086 (0.22 mumol kg-1, i.v.) attenuated the Paf-induced changes in BP, LVP and LV dP/dt. The dose-response curve for fall in BP was shifted to the right by one order of magnitude. 5. Histamine-induced cardiovascular changes (systemic hypotension and tachycardia) were not affected by prior administration of WEB 2086. 6. WEB 2086 should be of value in assessing the role of Paf in pathophysiological conditions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2758235      PMCID: PMC1854583          DOI: 10.1111/j.1476-5381.1989.tb11999.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  8 in total

1.  Effect of BN 52021, a specific PAF-acether antagonist, on cardiac anaphylaxis in Langendorff hearts isolated from passively sensitized guinea-pigs.

Authors:  M Koltai; I Lepran; L Szekeres; I Viossat; E Chabrier; P Braquet
Journal:  Eur J Pharmacol       Date:  1986-10-14       Impact factor: 4.432

Review 2.  Perspectives in platelet-activating factor research.

Authors:  P Braquet; L Touqui; T Y Shen; B B Vargaftig
Journal:  Pharmacol Rev       Date:  1987-06       Impact factor: 25.468

3.  Pathophysiological mechanisms of sudden death induced by platelet activating factor.

Authors:  A M Lefer; H F Müller; J B Smith
Journal:  Br J Pharmacol       Date:  1984-09       Impact factor: 8.739

4.  Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2.

Authors:  J E Heffner; S A Shoemaker; E M Canham; M Patel; I F McMurtry; H G Morris; J E Repine
Journal:  J Clin Invest       Date:  1983-02       Impact factor: 14.808

5.  Interference by the novel PAF-acether antagonist WEB 2086 with the bronchopulmonary responses to PAF-acether and to active and passive anaphylactic shock in guinea-pigs.

Authors:  M Pretolani; J Lefort; E Malanchère; B B Vargaftig
Journal:  Eur J Pharmacol       Date:  1987-08-21       Impact factor: 4.432

6.  Effects of acetyl glyceryl ether of phosphorylcholine (platelet activating factor) on ventricular preload, afterload, and contractility in dogs.

Authors:  J L Kenzora; J E Pérez; S R Bergmann; L G Lange
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

7.  Protective effect of WEB 2086, a novel antagonist of platelet activating factor, in endotoxin shock.

Authors:  J Casals-Stenzel
Journal:  Eur J Pharmacol       Date:  1987-03-17       Impact factor: 4.432

8.  Acetyl glyceryl ether phosphorylcholine. Intravascular alterations following intravenous infusion into the baboon.

Authors:  L M McManus; R N Pinckard; F A Fitzpatrick; R A O'Rourke; M H Crawford; D J Hanahan
Journal:  Lab Invest       Date:  1981-10       Impact factor: 5.662

  8 in total
  1 in total

Review 1.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.